quinazolines has been researched along with demecolcine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Griswold, DP; Hook, KE; Leopold, WR; Nelson, JM; Roberts, BJ | 1 |
Bamburg, JR; Bedford, JS; Bernstein, BW; Jha, MN | 1 |
2 other study(ies) available for quinazolines and demecolcine
Article | Year |
---|---|
Cell cycle effects of trimetrexate (CI-898).
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Survival; Cells, Cultured; Cricetinae; Demecolcine; Drug Evaluation, Preclinical; Female; Flow Cytometry; Injections, Intraperitoneal; Interphase; Leukemia L1210; Methotrexate; Mice; Neoplasms, Experimental; Ovary; Quinazolines; Trimetrexate | 1986 |
Caffeine eliminates gamma-ray-induced G2-phase delay in human tumor cells but not in normal cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Breast Neoplasms; Caffeine; Calcium Channel Blockers; Calcium Signaling; Carcinoma; Chickens; Demecolcine; Drug Resistance; Female; Fibroblasts; G2 Phase; Gamma Rays; HeLa Cells; Humans; Mitosis; Neoplastic Stem Cells; Neurons; Ovarian Neoplasms; Phosphodiesterase Inhibitors; Quinazolines; Radiation Tolerance; Ryanodine; Ryanodine Receptor Calcium Release Channel; Thapsigargin; Tumor Cells, Cultured | 2002 |